Rheumatic disease patients’ motivations and emotions related to the decision to participate in a clinical trial: preliminary findings
Abstract
Introduction: Clinical trials are extremely important in the development of modern therapies. Unfortunately, it is currently difficult to recruit patients for clinical trials, which involves increased costs and time. For this reason, increasing attention is being paid to patients' emotions and motivations related to clinical trial participation. Their thorough understanding can be crucial not only to persuade patients to participate in clinical trials but also keep them in the trial.
Aim: This study aims to identify which expectations regarding clinical trials have the greatest influence on the decision to participate in them among a group of patients with rheumatic diseases.
Material and methods: Sixty-nine (50K/19M) patients with rheumatic diseases were included in the study. The mean age of the patients was 50.8 ± 12.9 years and the mean disease duration was 13.1 ± 9.3 years. Patients included in the study were asked to complete a questionnaire with questions about their reasons for participating in clinical trials, their emotions about it and their attitudes towards clinical trials.
Results: In the study group, the predominant reason for participating in a clinical trial was to receive positive information about the trial from a rheumatologist, with 45 (70%) respondents giving this answer. The second most common reason for enrolling in a clinical trial was the lack of improvement during standard treatment, with 32 (46%) respondents. The most frequently reported emotion associated with entering a clinical trial was hope — 53 (77%) of respondents.
Conclusions: People with rheumatic diseases who decide to participate in a clinical trial most often make this decision based on a conversation with their attending physician, with motivations and hopes associated with improved efficacy of a new therapy.
Keywords: clinical trialsrheumatoid arthritispsoriatic arthritissystemic lupus erythematosusrheumatic diseases
References
- Thorwal J. Stulecie detektywów. Wydawnictwo Znak, Kraków 2019.
- Anderson A, Borfitz D, Getz K. Global Public Attitudes About Clinical Research and Patient Experiences With Clinical Trials. JAMA Netw Open. 2018; 1(6): e182969.
- Goldman DA. Thalidomide use: past history and current implications for practice. Oncol Nurs Forum. 2001; 28(3): 471–477.
- Krumholz HM, Ross JS, Presler AH, et al. What have we learnt from Vioxx? BMJ. 2007; 334(7585): 120–123.
- Truong TH, Weeks JC, Cook EF, et al. Altruism among participants in cancer clinical trials. Clin Trials. 2011; 8(5): 616–623.
- Locock L, Smith L, Locock L, et al. Personal benefit, or benefiting others? Deciding whether to take part in clinical trials. Clin Trials. 2011; 8(1): 85–93.
- Catania C, De Pas T, Goldhirsch A, et al. Participation in clinical trials as viewed by the patient: understanding cultural and emotional aspects which influence choice. Oncology. 2008; 74(3-4): 177–187.
- Godskesen T, Nygren P, Nordin K, et al. Phase 1 clinical trials in end-stage cancer: patient understanding of trial premises and motives for participation. Support Care Cancer. 2013; 21(11): 3137–3142.
- Udrea G, Dumitrescu B, Purcarea M, et al. Patients' perspectives and motivators to participate in clinical trials with novel therapies for rheumatoid arthritis. J Med Life. 2009; 2(2): 227–231.
- van Boheemen L, Ter Wee MM, Seppen B, et al. How to enhance recruitment of individuals at risk of rheumatoid arthritis into trials aimed at prevention: understanding the barriers and facilitators. RMD Open. 2021; 7(1).
- Obarska I. Nierówność w dostępie do leczenia biologicznego w chorobach autoimmunizacyjnych w Europie. Refundacja apteczna szansą na poprawę efektywności leczenia w Polsce. Polski Związek Pracodawców Przemysłu Farmaceutycznego, Warszawa 2022.
- https://med.stanford.edu/news/all-news/2019/07/novel-rheumatoid-arthritis-drug-succeeds-in-clinical-trial.html (14.03.2023).
